Loading company…
San Francisco biotech using machine learning and 3D bioprinted lymph node organoids to discover fully human antibodies.
Founded in 2016 and headquartered in San Francisco, US, Prellis Biologics, Inc. develops antibody discovery technology through its EXIS platform, which combines machine learning with 3D bioprinted lymph node organoids. It sells to biotech and pharmaceutical companies through licensing and collaborative research deals, earning upfront fees, milestones and royalties. In June 2022 the company completed a Series C co-led by Avidity Partners and Celesta Capital, bringing its total funding to USD 17.00 mn.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in